What is the recommended work‑up and management for an adult patient with suspected or confirmed cirrhosis?

Work-up and Treatment for Cirrhosis

All patients with suspected cirrhosis require immediate diagnostic confirmation (preferably by non-invasive elastography ≥15 kPa), etiology identification, screening for varices via upper endoscopy, hepatocellular carcinoma surveillance with ultrasound ± AFP every 6 months, and initiation of non-selective beta-blockers for portal hypertension prevention 1, 2.

Initial Diagnostic Work-up

Confirming Cirrhosis

• Elastography is the preferred non-invasive method: liver stiffness ≥15 kPa typically confirms cirrhosis without requiring biopsy 2
• Liver biopsy remains the gold standard but is reserved for unclear cases
• Approximately 40% of patients are diagnosed only when presenting with complications (ascites, hepatic encephalopathy), which carries poor prognosis 2

Identify the Etiology

Determine the underlying cause as treatment differs:

• Alcohol use disorder (~45% of cases)
• Nonalcoholic fatty liver disease (26%)
• Hepatitis C (41%)
• These etiologies frequently overlap 2

Baseline Laboratory Assessment

• Complete blood count, comprehensive metabolic panel
• Liver function tests (albumin, bilirubin, INR)
• Viral hepatitis serologies (HBV, HCV)
• Autoimmune markers if indicated
• Alpha-fetoprotein (AFP) for HCC screening baseline

Screening for Complications

Variceal Screening

• Upper endoscopy is mandatory at diagnosis to screen for esophageal and gastric varices 1
• Repeat endoscopy intervals depend on initial findings and Child-Pugh class

Hepatocellular Carcinoma Surveillance

• Ultrasound ± AFP every 6 months for all cirrhotic patients 2, 3
• Annual incidence of HCC is 1-4% in cirrhosis
• 5-year survival is only ~20% once HCC develops 2

Additional Screening

• Osteoporosis screening (DEXA scan) 3
• Vaccination status: hepatitis A, hepatitis B, pneumococcal, influenza, COVID-19 3

Treatment: Compensated Cirrhosis

Portal Hypertension Management

Non-selective beta-blockers (NSBBs) are first-line therapy to prevent variceal bleeding and decompensation 1, 2:

• Carvedilol or propranolol are preferred options
• In a 3-year RCT of 201 patients, NSBBs reduced decompensation or death from 27% to 16% 2
• NSBBs provide portal pressure reduction plus additional beneficial effects beyond bleeding prevention 1

Important caveats for NSBB use:

• Exercise caution with severe or refractory ascites (not an absolute contraindication) 1
• Avoid high doses 1
• Discontinue if: systolic BP <90 mmHg, active bleeding, sepsis, spontaneous bacterial peritonitis (SBP), or acute kidney injury (AKI) 1
• After recovery from acute illness, attempt reinstatement 1
• If NSBB intolerance persists, proceed with endoscopic band ligation (EBL) 1

Carvedilol specifically: Cannot be routinely recommended at present despite theoretical advantages 1

Lifestyle Modifications

• Absolute alcohol abstinence regardless of etiology
• Nutritional optimization
• Weight management for NAFLD-related cirrhosis
• Avoid hepatotoxic medications (NSAIDs, certain antibiotics)

Treatment: Decompensated Cirrhosis

Ascites Management

Combination diuretic therapy is superior to sequential therapy 2:

• Aldosterone antagonist (spironolactone) + loop diuretic (furosemide) initiated together
• Combination therapy achieved ascites resolution in 76% vs 56% with sequential initiation
• Lower hyperkalemia rates (4% vs 18%) with combination approach 2
• Typical starting doses: spironolactone 100 mg + furosemide 40 mg daily
• Sodium restriction <2 g/day

Hepatic Encephalopathy

Lactulose is first-line therapy with proven mortality benefit 2:

• Reduced mortality: 8.5% vs 14% compared to placebo (meta-analysis of 705 patients)
• Reduced recurrent overt encephalopathy: 25.5% vs 46.8% (meta-analysis of 1,415 patients) 2
• Titrate to 2-3 soft bowel movements daily
• Rifaximin can be added for refractory cases

Acute Variceal Hemorrhage

This is a medical emergency requiring immediate intensive care 1:

Immediate management (before endoscopy):

1. Volume resuscitation: crystalloids via large-bore IV access
2. Restrictive transfusion strategy: Hb threshold 7 g/dL, target 7-9 g/dL 1
3. Vasoactive drugs immediately (do not wait for endoscopy):
   • Terlipressin: 2 mg IV q4h × 48h, then 1 mg q4h
   • OR Somatostatin: 250 µg bolus, then 250 µg/h continuous infusion (can increase to 500 µg/h)
   • OR Octreotide: 50 µg bolus, then 50 µg/h continuous infusion 1
4. Antibiotic prophylaxis: Ceftriaxone 1 g IV daily (preferred) or norfloxacin for up to 7 days 1

Endoscopic management:

• Upper endoscopy within 12 hours of presentation 1
• Consider erythromycin 250 mg IV 30-120 min before endoscopy to improve visualization (avoid if QT prolongation) 1
• Endoscopic band ligation (EBL) is preferred over sclerotherapy 1
• For gastric varices: cyanoacrylate injection or EBL (only for small varices) 1

Post-procedure:

• Continue vasoactive drugs for 5 days to prevent early rebleeding 1
• Continue antibiotics for 7 days
• Early TIPS (within 72 hours) for high-risk patients (Child-Pugh C or Child-Pugh B with active bleeding at endoscopy)
• Rescue TIPS for rebleeding (~15% of cases) 1

Hepatorenal Syndrome

Terlipressin is the treatment of choice 2:

• In an RCT of 300 patients, terlipressin improved reversal rate from 18% to 39%
• Median survival without treatment is <2 weeks 2
• Annual incidence in patients with ascites is 8% 2

Spontaneous Bacterial Peritonitis

• Annual incidence in ascites patients: 11% 2
• Diagnostic paracentesis for any patient with ascites and clinical deterioration
• Empiric third-generation cephalosporin (ceftriaxone or cefotaxime)
• Albumin infusion to prevent hepatorenal syndrome

Symptom Management

Cirrhosis causes significant symptom burden that requires specific treatment 2:

• Muscle cramps (64% prevalence): pickle brine or taurine
• Pruritus (39% prevalence): cholestyramine, rifampin, or naltrexone
• Poor-quality sleep (63% prevalence): hydroxyzine
• Sexual dysfunction (53% prevalence): tadalafil for men

Monitoring and Follow-up

Compensated Cirrhosis

• Clinic visits every 3-6 months
• HCC surveillance ultrasound ± AFP every 6 months
• Repeat endoscopy per variceal screening protocols
• Monitor for signs of decompensation

Decompensated Cirrhosis

• More frequent monitoring (every 1-3 months or as needed)
• Consider telemedicine and remote monitoring to reduce hospital footfall and improve early detection of complications 4
• Structured discharge planning with patient/caregiver education to prevent readmissions 4

Liver Transplantation Evaluation

• Refer for transplant evaluation at first decompensation event
• Median survival after ascites onset: 1.1 years
• Median survival after hepatic encephalopathy onset: 0.92 years 2
• Transplantation is the only cure for cirrhosis

Common Pitfalls

• Do not assume all cirrhotic patients have bleeding tendency: coagulation is rebalanced, and thrombotic events can occur
• Do not continue NSBBs during acute illness: hypotension, sepsis, AKI, or bleeding require temporary discontinuation 1
• Do not delay vasoactive drugs waiting for endoscopy in suspected variceal bleeding—start immediately 1
• Do not use liberal transfusion strategies: restrictive approach (Hb 7-9 g/dL) improves outcomes 1
• Do not forget antibiotic prophylaxis in GI bleeding—it reduces mortality and improves bleeding control 1